1. Home
  2. MANE vs FTRE Comparison

MANE vs FTRE Comparison

Compare MANE & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MANE

Veradermics Incorporated Common Stock

N/A

Current Price

$47.12

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$10.63

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MANE
FTRE
Founded
2019
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
MANE
FTRE
Price
$47.12
$10.63
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
$15.39
AVG Volume (30 Days)
259.5K
2.0M
Earning Date
01-01-0001
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,723,400,000.00
Revenue This Year
N/A
$2.45
Revenue Next Year
N/A
$3.08
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.00
52 Week Low
$36.26
$3.97
52 Week High
$51.56
$18.67

Technical Indicators

Market Signals
Indicator
MANE
FTRE
Relative Strength Index (RSI) 67.60 34.30
Support Level $39.73 $9.35
Resistance Level $51.56 $11.46
Average True Range (ATR) 4.05 1.16
MACD 0.04 0.01
Stochastic Oscillator 70.52 26.76

Price Performance

Historical Comparison
MANE
FTRE

About MANE Veradermics Incorporated Common Stock

Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Share on Social Networks: